In a significant boost to the fight against lung cancer, HEPTA Medical, a pioneering medical device company specializing in minimally invasive thermal ablation therapy, has successfully completed a €5.7 million Series A funding round. The investment was led by BPI France and supported by M&L Healthcare and Clery IG.
Founded in 2019 by Sofinnova Partners through its medtech acceleration team MD Start, HEPTA Medical is poised to advance its cutting-edge microwave ablation platform. The newly acquired funds will facilitate the 510(k) regulatory approval process and support the initiation of pivotal clinical trials in the United States. The company’s microwave ablation technology promises a safe, efficient, and incision-less approach to treating early-stage lung cancer, a condition that remains the leading cause of cancer-related deaths globally.
Dr. Thomas Bancel, CEO of HEPTA Medical, expressed his enthusiasm about the development: “We are thrilled to have secured this investment, which will enable us to propel our microwave ablation therapy forward. Our recent achievement of securing a proprietary patent and upcoming preclinical trial results, to be unveiled at the CIRSE conference, mark crucial milestones in our journey.”
In addition to the funding, HEPTA Medical has fortified its leadership team with Gérard Hascoët, a Sofinnova Venture Partner, alongside Philippe Boucheron and Jocelyn Kum, representing BPI France and M&L Healthcare, respectively.
Philippe Boucheron, Deputy Chief of Life Sciences Investments at BPI France, highlighted the investment’s strategic importance: “HEPTA Medical’s innovative approach to thermal ablation therapy positions them at the forefront of transforming lung cancer care. We are eager to support their advancements and anticipate substantial contributions to improving patient outcomes.”
Editorial Opinion:
HEPTA Medical’s recent funding milestone underscores the growing investment and interest in innovative solutions for lung cancer treatment. With lung cancer screening programs expanding globally, the demand for effective and minimally invasive treatment options is higher than ever. HEPTA’s flexible microwave ablation probe, equipped with real-time temperature monitoring and predictive AI software, represents a significant leap forward in patient care. The integration of such advanced technology not only promises to enhance treatment efficacy but also reduces the procedural risks associated with traditional methods.
HEPTA Medical’s commitment to advancing healthcare technology through their collaboration with world-renowned centers and the pursuit of regulatory approvals highlights their strategic vision and dedication. Their innovative approach, coupled with strong backing from leading investors, positions them well to make a meaningful impact in the oncology field, potentially setting new standards in the treatment of early-stage lung cancer.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
